Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 52-week extension study of elobixibat in chronic idiopathic constipation
2012-005601-46Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elobixibat in functional constipation (FC), sponsored by Ferring Pharmaceuticals. Primary endpoint: Safety and tolerability. Started Mar 2013; status: completed.
02
Drugs
elobixibat
03
Conditions
functional constipation (FC)
Beyond the preview
Go deeper on 2012-005601-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005601-46.